O'Kennedy
Niamh O'Kennedy, Aberdeen GB
Patent application number | Description | Published |
---|---|---|
20090123584 | THERAPEUTIC USES OF TOMATO EXTRACTS - The present invention relates to tomato extracts or an active fraction thereof for use in preventing or inhibiting the initiation of venous thrombosis and fibrin clot formation in a vein. | 05-14-2009 |
20110206794 | FRUIT EXTRACTS - Provided are methods of making an extract of fruit of the Solanaceae family wherein fruit is processed to optimise the platelet aggregation inhibiting activity of the extract. The methods involve preparing a start mix of homogenised fruit; separating a water soluble fraction from fruit solids; filtration of the water soluble fraction; and concentration of active agents in the filtration permeate. The invention also provides fruit extracts manufactured by such methods, and also fruit extracts containing glycolsylated phenolic acid or a phenolic ester, or derivatives thereof; a glycosylated flavonoid; and a nucleoside. The extracts of the invention are useful as medicaments for the treatment or prevention of a medical condition characterised by inappropriate platelet aggregation. In particular, the medicaments may be of use in maintaining heart health by reducing platelet aggregation; benefiting the circulation; and/or normalizing or otherwise benefiting blood flow. | 08-25-2011 |
20110212913 | THERAPEUTIC COMPOSITIONS COMPRISING PHENOLIC ACIDS FOR TREATING CONDITIONS RELATED TO INAPPROPRIATE PLATELET AGGREGATION - The invention provides compositions comprising a therapeutically effective amount of a compound of general formula (I): wherein R1, R2 and R3 may be independently selected from H, OH and OMe; wherein X is C | 09-01-2011 |
Niamh O'Kennedy, Manchester GB
Patent application number | Description | Published |
---|---|---|
20090053340 | THERAPEUTIC USES OF TOMATO EXTRACTS - The invention provides the use of a water soluble tomato extract or an active fraction thereof for the manufacture of a medicament for lowering plasma triglyceride levels, the water soluble tomato extract or active fraction thereof being substantially free of lycopene and being substantially free from water-insoluble particulate material. | 02-26-2009 |
Niamh O'Kennedy, Berkshire GB
Patent application number | Description | Published |
---|---|---|
20110245213 | TREATMENT - The present invention concerns compositions that may be used in the prevention or treatment of medical conditions characterised by having an inflammatory component. The compositions comprise a therapeutically effective amount of an isothiocyanate (ITC). The composition may comprise further anti-inflammatory agents (e.g. plant-derived polyphenols). | 10-06-2011 |
Niamh O'Kennedy, Windsor GB
Patent application number | Description | Published |
---|---|---|
20120321732 | THERAPEUTIC USES OF TOMATO EXTRACTS - The present invention relates to tomato extracts or an active fraction thereof for use in preventing or inhibiting the initiation of venous thrombosis and fibrin clot formation in a vein. | 12-20-2012 |
20140147537 | FRUIT EXTRACTS - Provided are methods of making an extract of fruit of the Solanaceae family wherein fruit is processed to optimise the platelet aggregation inhibiting activity of the extract. The methods involve preparing a start mix of homogenised fruit; separating a water soluble fraction from fruit solids; filtration of the water soluble fraction; and concentration of active agents in the filtration permeate. The invention also provides fruit extracts manufactured by such methods, and also fruit extracts containing glycosylated phenolic acid or a phenolic ester, or derivatives thereof, a glycosylated flavonoid; and a nucleoside. The extracts of the invention are useful as medicaments for the treatment or prevention of a medical condition characterised by inappropriate platelet aggregation. In particular, the medicaments may be of use in maintaining heart health by reducing platelet aggregation; benefiting the circulation; and/or normalizing or otherwise benefiting blood flow. | 05-29-2014 |
Richard O'Kennedy, Dublin IE
Patent application number | Description | Published |
---|---|---|
20100317094 | MILK ANALYSIS MICROFLUIDIC APPARATUS FOR DETECTING MASTITIS IN A MILK SAMPLE - A milk analysis apparatus for detecting mastitis in a milk sample by isolating somatic cells in the form of a pellet using centrifugal sedimentation is described. The apparatus comprises a vessel for holding the milk sample, and a centrifuge for rotating the vessel. The vessel includes an inlet for facilitating charging milk into a body portion of the vessel; and a trap for capturing somatic cells suspended in the milk sample. The somatic cells are biased towards the trap upon rotation of the vessel. | 12-16-2010 |
20110034676 | ANTI-SIALIC ACID ANTIBODY MOLECULES - A method of generating and isolating a recombinant high affinity anti-sialic acid antibody molecule comprises the steps of immunising a host with an immunogen comprising a conjugate of sialic acid and a carrier protein to generate an anti-sialic acid polyclonal serum, isolating a sample of RNA from the immunised avian host, and generating and screening of a library of recombinant antibody molecules from the RNA sample, and isolating a recombinant high affinity anti-sialic acid antibody molecule. The antibody molecule is selected from the group consisting of: whole antibodies; scFv fragments; and Fab fragments, and the host is | 02-10-2011 |
Richard O'Kennedy, Dublin IL
Patent application number | Description | Published |
---|---|---|
20130190206 | Direct Clone Analysis and Selection Technology - The present invention describes a spatial addressing technique that uses a very high-density micro-pore array for high-throughput screening of biological interactions. The therapeutic, diagnostic and drug-discovery implications of being able to identify, select and characterize specific protein-protein, protein-DNA and/or protein-carbohydrate interactions from heterogeneous populations of millions (to billions) of cells is discussed. Importantly, this technique possesses the screening and selection capacity of current display-based screening systems (i.e., millions-billions) but with greater efficiency and shorter time. | 07-25-2013 |